Oral liquid compositions including valsartan

An oral liquid composition consisting of:

• about 28 mg/mL to about 36 mg/mL valsartan or a pharmaceutically acceptable salt or solvate thereof;
• about 1.0 mg/mL to about 100 mg/mL cyclodextrin;
• alkali salt;
• optionally, sorbate salt;
• optionally, paraben;
• optionally, at least one sweetener selected from the group consisting of glucose, fructose, sucrose, tagatose, sucralose, trehalose, maltodextrin, polydextrose, inulin, maltol, acesulfame, alitame, aspartame, neotame, sodium cyclamate, saccharin, neohesperidin dihydrochalcone, stevioside, and thaumatin;
• optionally, at least one flavoring agent selected from the group consisting of almond, anise, apple, apricot, bergamot, blackberry, blackcurrant, blueberry, bubblegum, cacao, caramel, cherry, cinnamon, clove, coffee, coriander, cranberry, cumin, dill, eucalyptus, fennel, fig, ginger, grape, grapefruit, guava, hop, lemon, licorice, lime, malt, mandarin, molasses, nutmeg, orange, peach, pear, peppermint, pineapple, raspberry, rose, spearmint, strawberry, tangerine, tea, tutti-frutti, vanilla, and wintergreen;
• and
• water;
• provided that a pH of the oral liquid composition is 7.5 to 9.0 and the valsartan or pharmaceutically acceptable salt or solvate thereof is fully solubilized in the oral liquid composition.

A method of treating coronary artery disease comprising administering to a patient in need thereof an oral liquid composition consisting of:

• about 60 mg/mL to about 68 mg/mL valsartan or a pharmaceutically acceptable salt or solvate thereof;
• about 1.0 mg/mL to about 100 mg/mL cyclodextrin;
• alkali salt;
• optionally, sorbate salt;
• optionally, paraben;
• optionally, at least one sweetener selected from the group consisting of glucose, fructose, sucrose, tagatose, sucralose, trehalose, maltodextrin, polydextrose, inulin, maltol, acesulfame, alitame, aspartame, neotame, sodium cyclamate, saccharin, neohesperidin dihydrochalcone, stevioside, and thaumatin;
• optionally, at least one flavoring agent selected from the group consisting of almond, anise, apple, apricot, bergamot, blackberry, blackcurrant, blueberry, bubblegum, cacao, caramel, cherry, cinnamon, clove, coffee, coriander, cranberry, cumin, dill, eucalyptus, fennel, fig, ginger, grape, grapefruit, guava, hop, lemon, licorice, lime, malt, mandarin, molasses, nutmeg, orange, peach, pear, peppermint, pineapple, raspberry, rose, spearmint, strawberry, tangerine, tea, tutti-frutti, vanilla, and wintergreen;
• and
• water;
• provided that a pH of the oral liquid composition is 7.5 to 9.0 and the valsartan or pharmaceutically acceptable salt or solvate thereof is fully solubilized in the oral liquid composition.